CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Financials Chongqing Zhifei Biological Products Co., Ltd.
Equities
300122
CNE100000V20
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.41 CNY | +1.00% |
|
-1.57% | -48.60% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 79,456 | 236,656 | 199,360 | 140,528 | 146,664 | 75,189 | - | - |
| Enterprise Value (EV) 1 | 80,690 | 238,093 | 195,858 | 139,911 | 143,334 | 67,017 | 60,378 | 50,617 |
| P/E ratio | 33.6 x | 71.7 x | 19.5 x | 18.6 x | 18.2 x | 7.26 x | 6.27 x | 7.16 x |
| Yield | 1.01% | 0.34% | 0.48% | 0.57% | 1.31% | 2.87% | 3.13% | 2.65% |
| Capitalization / Revenue | 7.5 x | 15.6 x | 6.5 x | 3.67 x | 2.77 x | 1.3 x | 1.19 x | 1.28 x |
| EV / Revenue | 7.62 x | 15.7 x | 6.39 x | 3.66 x | 2.71 x | 1.16 x | 0.95 x | 0.86 x |
| EV / EBITDA | 27.7 x | 59.1 x | 15.8 x | 15.4 x | 14.8 x | 5.75 x | 4.6 x | 4.04 x |
| EV / FCF | 102 x | 89.2 x | 29.8 x | 261 x | 17.8 x | 33.7 x | 7.76 x | 4.19 x |
| FCF Yield | 0.98% | 1.12% | 3.36% | 0.38% | 5.6% | 2.96% | 12.9% | 23.9% |
| Price to Book | 13.8 x | 28.7 x | 11.3 x | 5.8 x | 4.66 x | 1.92 x | 1.51 x | 1.33 x |
| Nbr of stocks (in thousands) | 2,400,000 | 2,400,000 | 2,400,000 | 2,400,000 | 2,400,000 | 2,393,790 | - | - |
| Reference price 2 | 33.11 | 98.61 | 83.07 | 58.55 | 61.11 | 31.41 | 31.41 | 31.41 |
| Announcement Date | 2/27/20 | 2/21/21 | 2/8/22 | 3/20/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10,587 | 15,190 | 30,652 | 38,264 | 52,918 | 57,803 | 63,269 | 58,873 |
| EBITDA 1 | 2,910 | 4,027 | 12,394 | 9,079 | 9,700 | 11,662 | 13,133 | 12,514 |
| EBIT 1 | 2,814 | 3,895 | 12,000 | 8,758 | 9,373 | 10,962 | 13,210 | 13,510 |
| Operating Margin | 26.57% | 25.64% | 39.15% | 22.89% | 17.71% | 18.96% | 20.88% | 22.95% |
| Earnings before Tax (EBT) 1 | 2,765 | 3,854 | 11,931 | 8,718 | 9,342 | 11,300 | 13,765 | 14,003 |
| Net income 1 | 2,366 | 3,301 | 10,209 | 7,539 | 8,070 | 10,319 | 12,265 | 10,725 |
| Net margin | 22.35% | 21.73% | 33.3% | 19.7% | 15.25% | 17.85% | 19.39% | 18.22% |
| EPS 2 | 0.9860 | 1.376 | 4.254 | 3.141 | 3.362 | 4.327 | 5.009 | 4.386 |
| Free Cash Flow 1 | 794.3 | 2,670 | 6,576 | 536.6 | 8,030 | 1,986 | 7,784 | 12,078 |
| FCF margin | 7.5% | 17.58% | 21.45% | 1.4% | 15.18% | 3.44% | 12.3% | 20.52% |
| FCF Conversion (EBITDA) | 27.29% | 66.31% | 53.06% | 5.91% | 82.79% | 17.03% | 59.27% | 96.52% |
| FCF Conversion (Net income) | 33.56% | 80.87% | 64.41% | 7.12% | 99.51% | 19.25% | 63.46% | 112.62% |
| Dividend per Share 2 | 0.3333 | 0.3333 | 0.4000 | 0.3333 | 0.8000 | 0.9022 | 0.9835 | 0.8331 |
| Announcement Date | 2/27/20 | 2/21/21 | 2/8/22 | 3/20/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 8,824 | 8,841 | 9,513 | 9,470 | 10,441 | 11,173 | 13,273 | 14,826 | 13,646 | 11,396 | 13,080 | 15,974 | 15,649 | 12,333 | 15,228 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | 2,612 | 3,918 | 4,794 | - | - |
| EBIT 1 | - | 2,126 | 2,269 | 2,105 | 2,142 | 2,242 | 2,397 | 2,711 | 2,668 | 1,738 | 1,737 | 2,730 | 2,921 | 3,089 | 2,292 | - |
| Operating Margin | - | 24.09% | 25.67% | 22.12% | 22.62% | 21.47% | 21.45% | 20.43% | 18% | 12.73% | 15.24% | 20.87% | 18.29% | 19.74% | 18.59% | - |
| Earnings before Tax (EBT) 1 | - | - | - | 2,090 | 2,129 | 2,235 | 2,392 | 2,570 | 2,657 | 1,723 | 1,734 | 2,535 | 3,802 | 4,603 | - | - |
| Net income 1 | 5,491 | - | - | 1,806 | 1,878 | 1,932 | 2,032 | 2,228 | 2,270 | 1,540 | 1,458 | 2,189 | 3,284 | 4,016 | - | - |
| Net margin | - | - | - | 18.99% | 19.83% | 18.5% | 18.19% | 16.79% | 15.31% | 11.28% | 12.79% | 16.74% | 20.56% | 25.66% | - | - |
| EPS 2 | - | 0.7533 | - | 0.7533 | 0.7800 | 0.8067 | 0.8467 | 0.9283 | 0.9400 | 0.6400 | 0.6090 | 0.8911 | 1.149 | 1.427 | 0.8400 | - |
| Dividend per Share 2 | - | 0.4000 | - | - | - | - | - | - | - | 0.8000 | - | 0.2706 | 0.2706 | 0.2706 | 0.2865 | 0.2865 |
| Announcement Date | 8/29/21 | 2/8/22 | 4/27/22 | 8/29/22 | 10/27/22 | 3/20/23 | 4/19/23 | 8/28/23 | 10/26/23 | 4/22/24 | 4/22/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 1,234 | 1,437 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 3,502 | 617 | 3,330 | 8,172 | 14,811 | 24,572 |
| Leverage (Debt/EBITDA) | 0.424 x | 0.3568 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 794 | 2,670 | 6,576 | 537 | 8,030 | 1,986 | 7,784 | 12,079 |
| ROE (net income / shareholders' equity) | 47.7% | 46.3% | 78% | 36.1% | 29.1% | 25.8% | 23.9% | 18.7% |
| ROA (Net income/ Total Assets) | 26.7% | 25.2% | 45.1% | - | 18.3% | 15.9% | 15.6% | 12.8% |
| Assets 1 | 8,876 | 13,079 | 22,648 | - | 44,118 | 64,817 | 78,621 | 84,114 |
| Book Value Per Share 2 | 2.390 | 3.440 | 7.360 | 10.10 | 13.10 | 16.40 | 20.80 | 23.70 |
| Cash Flow per Share 2 | 0.5700 | 1.460 | 3.540 | 0.8300 | 3.750 | 2.730 | 3.650 | 4.270 |
| Capex 1 | 573 | 827 | 1,932 | 1,452 | 966 | 1,418 | 1,617 | 1,077 |
| Capex / Sales | 5.41% | 5.44% | 6.3% | 3.8% | 1.83% | 2.45% | 2.56% | 1.83% |
| Announcement Date | 2/27/20 | 2/21/21 | 2/8/22 | 3/20/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
31.41
CNY
Average target price
57.38
CNY
Spread / Average Target
+82.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.60% | 10.39B | |
| +0.29% | 91.38B | |
| -2.37% | 38.68B | |
| +71.42% | 27.84B | |
| -12.31% | 16.05B | |
| -4.54% | 13.48B | |
| -10.83% | 11.73B | |
| +180.20% | 10.74B | |
| +1.42% | 8.94B | |
| -4.78% | 7.2B |
- Stock Market
- Equities
- 300122 Stock
- Financials Chongqing Zhifei Biological Products Co., Ltd.
